Introduction
Human PRL is a neuroendocrine polypeptide hormone primarily produced by the lactotrophs in the anterior pituitary gland of vertebrates. It is well established that hPRL is directly involved in the development and differentiation of normal mammary gland in mammalian species (Blackwell and Hammond, 1999; Clevenger et al., 1995; Nagasawa et al., 1985; Topper and Freeman, 1980; Vonderhaar, 1998) . Controversy, however, still exists regarding the role of hPRL in human breast cancer. Emerging evidence links hPRL to human breast cancer including: (a) the detection of biologically active hPRL in human breast cancer cells, which suggests that hPRL is produced locally as an autocrine/paracrine growth factor within the mammary gland (Clevenger et al., 1995; Ginsburg and Vonderhaar, 1995; Goffin et al., 1996, Goffin and Vonderhaar, 1999) ; (b) PRL receptor (PRLR) levels are significantly higher in human breast cancer cells than in normal breast epithelial cells (Kelly et al., 1991) ; (c) transgenic mice over expressing hPRL have a higher breast cancer incidence (Wennbo et al., 1997) and (d) the hPRL antagonist, hPRL-G129R, slows the growth rate of human breast cancer xymographs in nude mice (Chen et al., 2002) . These examples support hPRL's role as a mitogen in human breast cancer and suggest that its antagonist may have potential in treating human breast cancer.
Apoptosis plays a critical role in the regulation of cells that are either in a normal or cancerous state of growth. Key regulators that control apoptosis are kept highly controlled by the cells' internal machinery. One of the first and most widely studied regulators of apoptosis to be identified was Bcl-2, which is now known to be a part of a family of related proteins (Adams and Cory, 1998) . bcl-2 is a human protooncogene that when overexpressed, will ultimately lead to the inhibition of cell death (Korsmeyer, 1999) . It suppresses apoptosis by blocking the release of cytochrome c, a major component of cellular respiration, from the mitochondria, thus preventing the activation of caspases, a group of proteases that carry out the process of cell death (Kumar et al., 2000; Yin et al., 1994) . In human breast cancer cells, Bcl-2 and Bax, the inhibitor of Bcl-2, are constitutively expressed to tightly regulate apoptosis (Adams and Cory, 1998; Binder et al., 1996; Kumar et al., 2000; Yin et al., 1994) . One of many factors leading to breast malignancy is the up-regulation of bcl-2 gene expression, ultimately resulting in the inhibition of apoptosis (Green and Beere, 1999) . There are numerous molecules that can regulate Bcl-2. For example, IL-3 has been shown to increase the expression of bcl-2 in hematopoietic cell lines (Krumenacker et al., 1998) . Studies using Nb2 cells, a rat lymphoma cell line, show that bcl-2 is upregulated in immortalized cell lines (Krumenacker et al., 1998; Leff et al., 1996) . One of the more relevant studies involving bcl-2 demonstrated that treatment of Nb2 cells with PRL results in bcl-2 up-regulation and bax down-regulation (Krumenacker et al., 1998) . However, there have been no definitive studies linking hPRL to Bcl-2 activity in human breast cancer cells.
The identification of specific genes that are differentially expressed in response to exogenous treatments has been a subject of great interest to many researchers in the past. There are several methods to compare gene expression patterns in tissue cells, such as representational difference analysis, differential display, cDNA array hybridization and serial analysis of gene expression (DeRisi et al., 1996; Guiliano et al., 1999; Hakvoort et al., 1994; Oh et al., 1999; Zhan et al., 1997) . All these methods are able to detect different gene expression profiles, but a newly described technique called suppression subtractive hybridization (SSH) offers additional advantages (Kuang et al., 1998; Yang et al., 2000) . Briefly, SSH first uses mRNA from two populations of cells and converts them into cDNA. The cDNA from cells that contain differentially expressed genes is referred to as the 'tester' and the reference cDNA is referred to as the 'driver'. Both 'tester' and 'driver' cDNAs are first digested using a 4 base-cutter restriction enzyme to create shorter bluntended molecules. The ends of the tester cDNAs are modified by ligating adaptors that will serve as PCR primers. The 'tester' cDNAs are then hybridized with 'driver' cDNAs, which have no adaptors on their ends. Suppression PCR, using the adaptors as primers, is then performed to allow exponential amplification of the differentially expressed genes. SSH allows investigators to identify which genes are being turned on or off in one cell type versus another more quickly and easily than other techniques. It is also possible to compare expression profiles of the same cell line by treating a group of cells with a specific compound and using an untreated group as the control. This variation of SSH allows investigators to understand which genes are being expressed in response to a specific treatment of choice. SSH is valuable because it includes an amplification step and selection step that other methods do not, thus increasing the levels of differentially expressed genes while decreasing the levels of housekeeping genes that result in unnecessary background. The introduction of the cDNA microarray makes it possible to identify genes in a much more efficient manner. This emerging technique has proven to be an essential tool when attempting to identify which genes are responding to a certain condition (Oh et al., 1999; Yang et al., 2000) . By combining these two methods it is possible to obtain and identify differentially expressed genes with precision (Beck et al., 2001) .
In this study, we examined the profile of apoptosis related genes expressed by four human breast cancer cell lines upon treatment with either hPRL or hPRL-G129R. It was found that bcl-2 gene expression was increased following treatment of breast cancer cells with hPRL in both estrogen receptor (ER) positive cell lines and one of two ER negative cell lines tested. To confirm the evidence linking hPRL and Bcl-2, a quantitative method of RT -PCR and a Bcl-2 ELISA were used to measure both bcl-2 mRNA expression levels and protein levels in 11 human breast cancer cell lines after treatment with hPRL or hPRL-G129R. The data from these studies suggests that hPRL acts as an apoptosis inhibitor by increasing the expression of Bcl-2 in human breast cancer and that hPRL-G129R competitively inhibits Bcl-2 induction by hPRL.
Results
Profile of apoptosis genes in response to hPRL or hPRL-G129R in four human breast cancer cell lines
Comparisons of the relevant apoptosis related genes expressed in human breast cancer cells are shown in Figure 1 . hPRL-G129R treated T-47D and MCF-7 cells shown in Figure 1a ,c and hPRL treated in Figure  1b ,d, respectively. It appears that in both cases the only gene that was up regulated is bcl-2 (10-F). In Figure 1a , T-47D cells treated with hPRL-G129R exhibited a strong up-regulation of caspases, such as caspases-3 (11-A), -4 (11-F), -7 (11-I), -9 (11-L) and -10 (11-M). The Bcl-2 binding protein, BNIP 3 , was expressed in all but the MDA-MB-468 after hPRL-G129R treatment (Table 1 ). In the T-47D cells, the genes related to death receptors such as serine-threonine kinase 1 (12-H), DAXX (12-I), tumor necrosis factor-related apoptosis inducing ligand (14-F) and death domain receptor 3 (15-G) were up-regulated after hPRL-G129R treatment, although the gene for caspase-8 (11-J and 11-K), which is normally associated with death receptors, has not. In MCF-7 cells the gene BAD (10-O in Figure 1c) , an important member of the Bcl-2 family of proteins, was differentially expressed after hPRL-G129R treatment. There was no evidence of caspase expression in MCF-7 cells after hPRL-G129R treatment. Table 1 summarizes all apoptosis related differentially expressed genes in T-47D, MCF-7, BT-549 and MDA-MB-468 cells treated with either hPRL or hPRL-G129R that were probed on an apoptosis microarray. To our knowledge, this is the first time that a list of apoptosis related differentially expressed genes has been compiled for these four breast cancer cells after treatment with hPRL and its antagonist.
Quantitative RT -PCR measurement of bcl-2 mRNA in 11 human breast cancer cell lines To confirm that hPRL induced the expression of bcl-2, quantitative real time RT -PCR was used. Figure 2a represents direct real time RT -PCR output from T-47D cells treated with either hPRL or hPRL-G129R and compared to the untreated control. bcl-2 message levels were clearly elevated in the hPRL treated samples as indicated by the amplification curves shift to the left and decrease in the hPRL-G129R treated samples as indicated by the amplification curves shift to the right, relative to untreated samples. All samples were normalized to equivalent levels of b-actin mRNA (Figure 2b ). Table 2 represents the bcl-2 levels from multiple quantitative real time RT -PCR runs relative to normalized levels of b-actin. The data is presented as levels of bcl-2 in all 11 cell lines treated with hPRL, hPRL-G129R or a combination of hPRL and hPRL-G129R, and were compared to levels of bcl-2 in the untreated controls. The responses are graphed as the per cent change of the experimental response to the untreated control+s.e. and shown in Figure 3 . In MCF-7 and MDA-MB-134 cells, hPRL treatment resulted in a highly significant (P50.01) up-regulation of bcl-2 message, while in BT-549 and T-47D cells the per cent change was significant (P50.05). In the remaining seven cell lines, bcl-2 message levels were not significantly different from the untreated controls. Treatment with the antagonist resulted in significantly (P50.05) decreased expression of bcl-2 message in four of the cell lines (MCF-7, T-47D, BT-549 and MDA-MB-157) with no significant change in the other cell lines. A modest increase in bcl-2 message expression was observed in four cell lines (MDA-MB-436, MDA-MB-468, MDA-MB-231, BT-483) following hPRL-G129R treatment. In seven cell lines a combination treatment of hPRL-G129R and hPRL resulted in lower levels of bcl-2 expression than the hPRL treatment alone (MCF-7, T-47D, MDA-MB-134, MDA-MB-453, BT-474, MDA-MB-231 and BT-483). The combination treatment significantly (P50.05) reduced bcl-2 expression levels in MCF-7 and T-47D cell lines, whereas MDA-MB-134, MDA-MB-453, BT-474, MDA-MB-231 and BT-483 cells show an insignificant decrease in the level of bcl-2.
Overexpression of Bcl-2 protein in various cell lines
To further confirm that Bcl-2 was upregulated in human breast cancer cells, a Bcl-2 ELISA was performed on all 11 cell lines. Data is presented as per cent change of Bcl-2 levels in cells treated with hPRL (100 ng/ml) or in cells treated with hPRL-G129R (500 ng/ml) and the combination of hPRL (100 ng/ml) and hPRL-G129R (500 ng/ml) over cells with no treatment. Figure 4a illustrates that six of the 11 human breast cancer cell lines tested showed a highly significant increase (P50.01) in Bcl-2 protein levels after treatment with hPRL. T-47D, MDA-MB-157 and MDA-MB-134 demonstrated the highest levels of Bcl-2 with an increase of approximately 175% over untreated cells. MCF-7, BT-549 and MDA-MB-483 all exhibited levels of Bcl-2 with an increase of approximately 125% over the untreated cells. MDA-MB-468, MDA-MB-453 and BT-474 demonstrated a less significant (P50.05) per cent change of Bcl-2 levels after treatment with hPRL. The remaining two cell lines, MDA-MB-436 and MDA-MB-231, did not demonstrate a significant level of Bcl-2 increase after treatment with hPRL. It is clear from Figure 4b that upon treatment with hPRL-G129R (500 ng/ml), there was a highly significant (P50.01) decrease in the levels of Bcl-2 in all 11 cell lines. The combination treatment of hPRL and hPRL-G129R demonstrated a highly significant (P50.01) decrease of Bcl-2 protein in nine of the 11 cell lines (Figure 4c ). MDA-MB-436 and BT- 
Discussion
Apoptosis, or programmed cell death, is a means of regulating cellular growth and differentiation without the inflammatory response generally induced by necrotic cell death (Adams and Cory, 1998) . During mammary gland development, and more importantly involution, key apoptosis-inducing Bcl-2 family proteins, such as Bax, Bad and Bcl-w are up regulated (Li, 1997; Schorr et al., 1999a) , and Bcl-2 appears to act as a regulator of Bax levels. It has been well established that decreased levels of Bax are correlated to increased levels of Bcl-2 and that this Bax/Bcl-2 ratio is also critical to normal breast development (Reed, 1998; Green, 2000; Adams and Cory, 1998) . Increases in levels of Bcl-2 appear to be more important to cell survival than the down-regulation of Bax (Schorr et al., 1999b) . The bcl-2 oncogene has been shown to have an anti-apoptotic function and may play a role in tumorigenesis by raising the threshold for apoptosis (Adams and Cory, 1998) . In our previous studies, we reported that an hPRL Cells were either treated with hPRL or hPRL-G129R as indicated. Genes that were differentially expressed are represented with a '+' symbol below the treatment that stimulated their expression and when not expressed the field was left blank as shown antagonist, hPRL-G129R, is able to inhibit human breast cancer cell proliferation through the induction of apoptosis (Chen et al., 1999) , suggesting that the role of hPRL in breast cancer cells may be antiapoptotic. We have also shown that hPRL downregulates TGFb1 (apoptotic factor) and up-regulates TGFa (survival factor) secretion in a dose-dependent manner in human breast cancer cells (Ramamoorthy et al., 2001) . More importantly, hPRL-G129R up-regulates TGFb1 and down-regulates TGFa. In the same study it was also shown that caspase-3 is up regulated by hPRL-G129R. In the present study, we looked at a vast array of genes within breast cancer cells that are responding to treatment with hPRL and hPRL-G129R. We provide evidence that the potential tumorigenic effects (autocrine and paracrine) of hPRL may be mediated through the up-regulation of Bcl-2. Numbers represent real time RT -PCR data correlating to Figure 3 and represent bcl-2 message levels. Cells were either treated with hPRL (500 ng/ml) or hPRL-G129R (500 ng/ml). Combination treatement (PRL+G129R) is as follows: 200 ng/ml PRL+1000 ng/ ml G129R for 48 h. All values are represented as fold change over the untreated controls and are mean+s.e. a n=2 -5; b n=2 -4; c n=2 -3 Figure 3 Real-time quantitative measurement of bcl-2 mRNA levels in 11 breast cancer cell lines in response to 48 h treatments with hPRL (500 ng/ml; a), hPRL-G129R (500 ng/ml; b) and a combination treatment of hPRL (200 ng/ml) and hPRL-G129R (1000 ng/ml; c). Levels are represented as the fold change over the untreated controls, and numbers are presented as mean+s.e. a, n=2 -5; b, n=2 -4; c, n=2 -3. **P50.01 versus basal levels of Bcl-2; *P50.05 versus basal levels of Bcl-2
The microarray studies using four breast cancer cell lines implied the heterogeneous nature of human breast cancer (Table 1) . It is apparent in the gene expression patterns of four cell lines that the gene bcl-2 is overexpressed in T-47D, MCF-7 and BT-549 breast cancer cells following hPRL treatment. In response to hPRL-G129R treatment, BNIP3, a 19-KD dimeric mitochondrial protein that binds to Bcl-2 and suppresses its anti-apoptotic activity (Chen et al., 1997) , is up-regulated in three of the four cell lines (Table 1) . These data suggest an additional role for hPRL in regulation of Bcl-2 activity in breast cancer cells. To further confirm this finding, we utilized 11 breast cancer cell lines and treated them with hPRL, hPRL-G129R or a combination of the two and measured bcl-2 mRNA as well as Bcl-2 protein levels. Increases in bcl-2 mRNA levels in four cell lines (MCF-7, MDA-MB-134, T-47D and BT-549) are highly significant (P50.01) following treatment by hPRL and are down regulated by hPRL-G129R treatment in five cell lines (MCF-7, MDA-MB-134, T-47D and BT-549 and MDA-MB-157) (Figure 3) . However, the response of Bcl-2 to the treatment of hPRL or hPRL-G129R was most apparent at the Bcl-2 protein level (Figure 4) . Eight of the 11 cell lines demonstrated a highly significant increase of Bcl-2 protein after hPRL treatment (P50.01). The maximum increase in Bcl-2 protein after a single dose treatment with hPRL was several fold higher than the basal level in untreated controls. In contrast, the decrease of Bcl-2 levels in response to treatment by hPRL-G129R was highly significant (P50.01) in all 11 cell lines ( Figure  4 ). The cell lines (MDA-MB-436, MDA-MB-468, MDA-MB-453, BT-474, MDA-MB-231 and BT-483) demonstrated no statistically significant bcl-2 response to hPRL treatment at the mRNA level, and showed a relatively lower response at the protein level. This would suggest that in these cell lines hPRL plays a less significant role in maintaining proliferation via the Bcl-2 protein. The discrepancy between the Bcl-2 mRNA levels and the protein levels in some cell lines after treatment may be attributed to many factors, which include the general instability of mRNA in the cells, relative to protein, where Bcl-2's half-life is greater than 10 h (Merino et al., 1994) .
The cell lines used in the cDNA subtraction experiments have been reported to produce PRL as an autocrine/paracrine growth factor, from the work of others (Ginsburg and Vonderhaar, 1995; Shaw-Bruha et al., 1997; Yamauchi et al., 2000) . We do not have evidence, at this point, that hPRL-G129R contains an intrinsic ability to elicit novel signal transduction of its own. Rather, we believe that the down regulation of the bcl-2 expression by hPRL-G129R is through the competitive inhibition of the effects induced by endogenous PRL. These findings are consistent with those of Llovera et al. (2000) , who have found that the hPRL-G129R does not activate any specific signaling molecules in their systems.
We found no obvious correlation between the published (Ormandy et al., 1997) ER status and the bcl-2 response following hPRL and hPRL-G129R treatment. For example, both the ER negative BT-549 and the most ER positive MDA-MB-134 cell lines demonstrated high levels of bcl-2 response, while the strongly ER positive cell line BT-483 and the ER negative MDA-MB-231 cell lines had the lowest responses. In our previous work, we determined relative PRLR mRNA expression levels in 11 breast Figure 4 Expression of the Bcl-2 protein in various cell lines. Cells were treated with either hPRL (100 ng/ml; a), hPRL-G129R (500 ng/ml; b) or a combination of hPRL (100 ng/ml) and hPRL-G129R (500 ng/ml, c) for 48 h, lysed and ELISAs were performed to determine the relative levels of Bcl-2 present in the cells. All cells were assayed in triplicate and levels of Bcl-2 was determined using a standard curve prepared using known Bcl-2 standards from the manufacture. Fold induction and inhibition were determined using untreated cells as a control for hPRL treated cells and hPRL treated cells as a control for the combination treatment. Cell lines are arranged from left to right in order of increasing bcl-2 mRNA message level (Figure 3. ). Numbers are presented mean+s.e. of at least three independent experiments. **P50.01 versus basal levels of Bcl-2; *P50.05 versus basal levels of Bcl-2 cancer cell lines (Peirce and Chen, 2001) . In this study, the levels of bcl-2 expression do not appear to have a linear correlation with that of PRLR mRNA. This might be attributed to the fact that there are multiple intracellular signaling mechanisms involved in regulation of bcl-2 expression. For example, there is recent evidence of cross-talk between PRL receptor and HER2/neu through phosphorylation of Jak2 that leads to the activation of MAP kinases in breast cancer cell lines (Yamauchi et al., 2000) . Related to this finding, we have seen that MAP kinases are, in fact, up regulated by PRL treatment in three out of four cell lines (Table 1) . Further work in this area should help to identify the specific pathways by which cellular apoptosis is regulated by hPRL and hPRL-G129R.
cDNA microarrays provide a powerful means for identifying genes differentially expressed in cells after certain alterations. However, the vast amount of information revealed after array analyses often leaves more questions than answers. In this study, we decided to focus on one gene, bcl-2, after analysing initial results of the cDNA subtraction and array analysis. There are clearly many questions to be addressed (Table 1) . For example, we found that there was no evidence of caspase expression in MCF-7 cells following treatment by hPRL-G129R, whereas caspase expression is up regulated in T-47D, BT-549 and MDA-MB-468 cells. We previously reported that caspase-3 activity was up regulated in T-47D cells following treatment with hPRL-G129R (Ramamoorthy et al., 2001) . There is a lack of caspase mRNA expression and the appearance of a more direct link to Bcl-2 related apoptosis via the BAD (Bcl-2 associated death promoter) protein in MCF-7 cells (Figure 1c ). During apoptosis, BAD has been shown to bind to Bcl-2 and release it from the mitochondrial membrane resulting in total cellular disruption. BAD operates upstream of the caspase pathway suggesting that MCF-7 cells activate apoptosis via a different pathway utilized by the other three breast cancer cell lines. It has been previously shown that MCF-7 cells lack caspase-3 entirely due to a 47-base pair deletion within the CASP-3 gene, although this cell line is still able to undergo apoptosis even in the absence of DNA fragmentation (Janicke et al., 1998; Liang et al., 2001) . Thus, our data tentatively identifies one component of the caspase-3 independent signaling pathway that MCF-7 cells may use to trigger apoptosis. It is also interesting to point out that a death domain protein, the receptor-interacting protein (RIP), is differentially expressed in all four cell lines following hPRL-G129R treatment. It has been reported that over-expression of RIP induces both NF-kB activation and apoptosis (Hsu et al., 1996) . Our results may be of interest when investigating the death domain proteins and death domain receptors in relation to hPRL and hPRL-G129R.
In summary, a list of apoptosis related genes that are differentially expressed following treatment with either hPRL or hPRL-G129R has been compiled for four different breast cancer cell lines. These data will allow for future studies of specific genes that are involved with cellular proliferation or apoptosis in human breast cancer. By focusing on Bcl-2 mRNA or protein expression in response to hPRL and hPRL-G129R treatment in 11 cell lines, we provide further evidence that the anti-apoptotic effects of hPRL in breast cancer are likely mediated through the up regulation of Bcl-2. It is generally accepted that, for cancer therapy, one should not design an approach based solely upon increasing death signals, such as chemotherapeutics. Rather, a twofold approach combining chemotherapeutics with removal of survival factors will result in a more efficient treatment. Our data regarding hPRL-G129R further strengthens its potential therapeutic role in breast cancer therapy. 
Materials and methods

Cell lines and growth conditions
PCR-Select cDNA suppression subtraction hybridization
Before experiments, cells were split into three groups of 10 T75 flasks and grown in their specific medium supplemented with 10% charcoal-stripped fetal bovine serum (CSS) until 80% confluent. Approximately 1610 8 cells from each group were treated with either 500 ng/ml of hPRL (hPRL was kindly supplied by Dr AF Parlow, National Hormone and Pituitary Program, NIH, USA) or 500 ng/ml of hPRL-G129R in cell specific media supplemented with 1% CSS. The untreated control cells were cultured in their respected medium supplemented with 1% CSS. All cells were treated for 48 h and immediately harvested for mRNA extraction. Polyadenylated mRNA was isolated using the Micro-Fast Track 2.0 kit (Invitrogen, Carlsbad, CA, USA) according to manufacturer's instructions. RNA yield was determined by measuring absorbency at 260 nm. SSH was performed using the PCR-Select TM cDNA Subtraction Kit (Clontech, Palo Alto, CA, USA) as previously described (Beck et al., 2001) . Three micrograms of purified cDNAs from the subtraction hybridizations were random primed labeled with alkali labile digoxigenin-dUTP using the DIG DNA Labeling Kit (Roche Molecular Biochemical's, Mannheim, Germany) according to the manufacturer's protocol.
cDNA microarrays
The Atlas TM human apoptosis array (Clontech) was used for all microarray analyses. The array is a nylon membrane that contains all known apoptosis related genes (205 cDNAs) spotted onto the surface in duplicate. Membranes were prehybridized with DIG Easy Hyb solution (Roche) overnight at 378C in a hybridization incubator with gentle rotation. DIGlabeled probes were purified and resuspended appropriately in TE (pH 8.0). The probes were boiled for 10 min and placed on ice for 5 min. After prehybridization, the DIGlabeled probe was added to the microarray membrane in a total volume of 5 ml of fresh DIG Easy Hub and allowed to hybridize overnight at 688C in a hybridization incubator with gentle rotation. Membranes were washed twice at 388C for 5 min in 26 SSC, 1% SDS, and twice at 688C for 15 min in 0.16 SSC, 0.5% SDS. DIG-labeled cDNAs on the hybridized Atlas TM membranes were detected by chemiluminescence using the DIG luminescent detection kit (Roche) according to the manufacturer's specifications using CSPD 1 as the chemiluminescent substrate. After incubation with CSPD 1 , membranes were placed in an autoradiography cassette and incubated at 378C for 15 min to enhance the exposure and then exposed to Kodak Biomax TM -MR film at room temperature (all hybridizations were carried out in duplicate). It was determined that using 3 mg of differentially expressed cDNAs for labeling and probing the microarrays was the correct amount for less background and optimal brightness for gene identification. Each array was exposed to the film for various periods of time to allow for the correct exposure to be captured.
Real time quantitative RT -PCR
Before treatment, 11 breast cancer cell lines were depleted of serum for 3 to 4 days in their respective medium supplemented with 1% CSS. Approximately 0.5 -167 7 cells from each group were treated with 500 ng/ml of hPRL, 500 ng/ml of hPRL-G129R or a 1000 ng : 250 ng ratio of hPRL-G129R to hPRL in cell specific medium supplemented with 1% CSS. The untreated control cells were cultured in cell specific medium supplemented with 1% CSS. All cells were treated for 48 h and harvested for total RNA extraction using the RNAqueous (Ambion, Austin, TX, USA) RNA isolation kit.
A one-step real time reverse transcription PCR (RT -PCR) technique was used to determine relative expression levels of bcl-2 mRNA using the ABI Perkin Elmer Prism 7700 Sequence Detection System (Perkin-Elmer Biosystems, Foster City, CA, USA). The reaction mix included a pre-developed TaqMan 1 assay mixture containing both forward and reverse bcl-2 specific primers and a 100 nm final concentration of the bcl-2-specific probe labeled with FAM reporter fluorescent dye (Perkin-Elmer 4319432F). A one-step reaction mixture provided in the TaqMan 1 Gold RT -PCR Kit (Perkin-Elmer) was used for all amplifications (5.5 mM MgCl 2 , 50 mM KCl, 0.01 mM EDTA, 10 mM Tris-HCl pH 8.3, 300 mM deoxyATP, 300 mM deoxyCTP, 300 mM deoxyGTP, 600 mM deoxyUTP, 0.025 U/ml AmpliTaq Gold DNA polymerase, 0.25 U/ml MultiScribe Reverse Transcriptase, 0.4 U/ml RNase inhibitor). Cycle parameters for the one-step RT -PCR included a reverse transcription step at 488C for 30 min followed by 40 cycles of 958C denaturation and 608C annealing/extension. Four hundred to 1500 ng of total RNA was used per reaction. The housekeeping gene bactin was used for internal normalization. Each reaction was carried out in triplicate for each PCR run, and each run was repeated two to five times. Data are expressed as the mean+s.e.
Bcl-2 ELISA
A Bcl-2 ELISA (Oncogene Research Products, Boston, MA, USA) analysis was performed according to manufacturer's instructions. Briefly, all 11 cell lines were treated with hPRL (100 ng/ml), hPRL-G129R (500 ng/ml) or combination of hPRL (100 ng/ml) and hPRL-G129R (500 ng/ml) for 48 h in depleted media specific for each cell line described previously. Controls for all treatments were those of untreated cells in their specific defined media. For each cell line, approximately 5610 6 cells were resuspended in 1 ml of resuspension solution (50 mM Tris, 5 mM EDTA, 0.2 mM PMSF, 1 mg/ ml pepstatin and 0.5 mg/ml leupeptin; pH adjusted to 7.4). Two hundred microliters of antigen extraction agent (Oncogene) were added to the cell suspensions and incubated on ice for 30 min. Cell debris was centrifuged and supernatant was frozen until use. Each supernatant was diluted 1 : 1 to obtain an optimal reading in the range of the standards. Standards were performed in duplicate. Analyses were repeated three times and data are expressed as the mean+s.e.
Statistical analyses
All values are given as mean+s.e. Statistical analysis was performed using the program StatsDirect version 1.9.8 (CamCode, Cambridge, UK) with one way ANOVA and a Tukey-Multiple Comparison test. P-values less than 0.01 were considered highly statistically significant and P values that were less than 0.05 were considered statistically significant.
